©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Regulatory Role of CD38 (ADP-ribosyl Cyclase/Cyclic ADP-ribose Hydrolase) in Insulin Secretion by Glucose in Pancreatic Cells
ENHANCED INSULIN SECRETION IN CD38-EXPRESSING TRANSGENIC MICE (*)

(Received for publication, August 10, 1995; and in revised form, September 20, 1995)

Ichiro Kato (1) Shin Takasawa (1) Atsuya Akabane (1) Osamu Tanaka (3) Hiroshi Abe (3) Toshinari Takamura (1) Yu Suzuki (1) Koji Nata (1) Hideto Yonekura (1) Takashi Yoshimoto (2) Hiroshi Okamoto (1)(§)

From the  (1)Departments of Biochemistry and (2)Neurosurgery, Tohoku University School of Medicine, Sendai 980-77, Miyagi, Japan and the (3)Division of Human Structure and Function, Department of Morphology, Tokai University School of Medicine, Isehara 259-11, Kanagawa, Japan

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Cyclic ADP-ribose (cADPR) serves as a second messenger for Ca mobilization in insulin secretion, and CD38 has both ADP-ribosyl cyclase and cADPR hydrolase activities (Takasawa, S., Tohgo, A., Noguchi, N., Koguma, T., Nata, K., Sugimoto, T., Yonekura, H., and Okamoto, H.(1993) J. Biol. Chem. 268, 26052-26054). Here, we produced transgenic mice overexpressing human CD38 in pancreatic beta cells. The enzymatic activity of CD38 in transgenic islets was greatly increased, and ATP efficiently inhibited the cADPR hydrolase activity. The Ca mobilizing activity of cell extracts from transgenic islets incubated in high glucose was 3-fold higher than that of the control, suggesting that ATP produced by glucose metabolism increased cADPR accumulation in transgenic islets. Glucose- and ketoisocaproate-induced but not tolbutamide- nor KCl-induced insulin secretions from transgenic islets were 1.7-2.3-fold higher than that of control. In glucose-tolerance tests, the transgenic serum insulin level was higher than that of control. The present study provides the first evidence that CD38 has a regulatory role in insulin secretion by glucose in beta cells, suggesting that the Ca release from intracellular cADPR-sensitive Ca stores as well as the Ca influx from extracellular sources play important roles in insulin secretion.


INTRODUCTION

Cyclic ADP-ribose (cADPR) (^1)(1) induces the release of Ca from microsomes of pancreatic islets (2, 3) and from a variety of other cells(4, 5, 6, 7, 8, 9, 10) . Glucose raises the cADPR concentration in islets, and cADPR induces insulin secretion from digitonin-permeabilized islets in vitro(3) . We have therefore suggested that cADPR plays a second messenger role in Ca mobilization for insulin secretion(2, 3, 11) . Human lymphocyte antigen CD38 (12, 13) has been shown to have both ADP-ribosyl cyclase and cADPR hydrolase activities (11, 14) . CD38 was found to be expressed in a variety of tissues and cells including pancreatic islets(11, 15) . We have shown that ATP, which is generated during glucose metabolism in islets, inhibits the cADPR hydrolase activity of CD38, thereby increasing the accumulation of cADPR because of decreased destruction(11) . CD38 is thus thought to play a central role in glucose-induced insulin secretion in islets. In the present study, we produced transgenic mice overexpressing CD38 in islets and analyzed the subcellular localization of expressed CD38, changes in Ca mobilizing activity, and glucose-induced insulin secretion.


EXPERIMENTAL PROCEDURES

Construction of Rat Insulin II Promoter/Human CD38 Hybrid Gene

A rat insulin II promoter previously reported to be active in pancreatic beta cells of transgenic mice (16, 17) was employed. The 0.7-kilobase pair BamHI-XmaI fragment (17) of the rat insulin II promoter (nucleotides -695 to +22 in (18) ), the 0.9-kilobase pair XmaI-SalI fragment of the human CD38 cDNA (11, 13) (nucleotides +58 to +980 in (13) ; XmaI and SalI sites introduced by polymerase chain reaction), and the 1.6-kilobase pair SalI-EcoRI fragment of the SV40 intron and polyadenylation signal (19) (SalI site derived from plasmid sequence) were ligated at the XmaI and SalI sites in the correct orientation. The resultant hybrid gene (Ins-CD38; 3.2 kilobase pairs) was separated from the plasmid vector pBlueScript SK- (Stratagene) by KpnI and NotI and was microinjected into fertilized eggs as described (17) .

Northern Blot Analyses

Northern blot analyses were carried out on total RNA extracted from various tissues as described (17) using a P-labeled human CD38 cDNA probe (EcoRI-EcoRI fragment of 528 base pairs; nucleotides +29 to +556 in (13) ). Hybridization signals were scanned with a bioimage analyzer, BAS 2000 (Fuji Photo Co., Ltd., Tokyo, Japan).

Immunohistochemical Analysis

Immunohistochemical analysis was carried out as described (17) using the diluted (1:20) monoclonal antibody to human CD38 (T16; Cosmo Bio, Japan) and an avidin-biotin peroxidase kit (Vector, Burlingame, CA).

Measurement of cADPR and ADPR Formations from NAD

Transgenic (lines 18 and 56) and nontransgenic islets were isolated in parallel from 6-10-week-old litters by the collagenase digestion method(20) . Five hundred islets were sonicated at 4 °C for 15 s in 0.1 ml of the homogenizing buffer (20 mM Hepes, pH 7.2, containing 1 mM MgCl(2), 0.1 mM EGTA, and 10 µg/ml aprotinin). Formations of cADPR and ADPR from NAD were measured as described(11, 21) ; briefly, the islet cell homogenate (10 µg of protein) was incubated for 10 min at 37 °C in 0.1 ml of phosphate-buffered saline (pH 7.4) with 0.2 mM NAD containing 5 µCi of [P]NAD (DuPont NEN). Reaction products were analyzed by high pressure liquid chromatography (HPLC) using a flow scintillation analyzer (Flow-One Beta-525TR, Packard, Meriden, CT).

Subcellular Fractionation and Measurement of NADGlycohydrolase Activity

The subcellular fractionation was performed according to the islet fractionation method of McDaniel et al.(22) . One thousand islets were homogenized in 400 µl of homogenizing buffer (50 mM MES, 1 mM EDTA, and 0.25 M sucrose, pH 7.2). The homogenate was centrifuged at 600 times g for 5 min to yield a pellet containing nuclei (nuclear fraction). Centrifugation of the supernatant at 20,000 times g for 20 min yielded a pellet containing the plasma membrane, secretory granules, and mitochondria (membrane fraction). Centrifugation of the resultant supernatant at 150,000 times g for 90 min yielded a pellet containing the microsome (microsome fraction). The supernatant after 150,000 times g centrifugation yielded a soluble protein (cytosol fraction). NAD glycohydrolase activity in the fractionated protein was measured as described(23) . Briefly, 1 µg of each fractionated protein was incubated with 0.2 mM NAD containing 50 nCi of [^14C]NAD (Amersham Corp.) at 37 °C for 10 min. The mixture was applied on a column of Dowex-1 (Bio-Rad Laboratories). Nicotinamide was eluted with 20 mM Tris-HCl (pH 7.5), followed by scintillation counting.

Measurement of Insulin Secretion from Isolated Islets

Islets of transgenic mice (line 18) and control mice were isolated in parallel from 6-10-week-old litters by collagenase digestion. Twenty islets were incubated for 1 h at 37 °C in 1 ml of RPMI 1640 medium containing 10% fetal calf serum and various concentrations of glucose. The medium samples were subsequently assayed for radioimmunoassay of insulin using the insulin radioimmunoassay kit (Amersham Corp.) and rat insulin standards. For the time course experiment, 20 islets were incubated at 37 °C in 1 ml of the medium containing 11.1 mM glucose, and medium samples (2 µl) collected at 10, 20, 30, and 40 min after the incubation were subjected to radioimmunoassay for insulin. For measurements of insulin secretion by other insulin secretagogues, 10 islets were incubated for 1 h at 37 °C in 0.5 ml of the medium containing the lowest concentration of glucose (2.5 mM) and then incubated for another 1 h in the same medium containing 10 mM ketoisocaproic acid (KIC) (Sigma), 0.2 mM tolbutamide (Sigma), or 25 mM KCl (Merck). The medium samples were subsequently radioimmunoassayed for insulin.

Assay of CaMobilizing Activity

Five hundred transgenic islets (line 18) or control islets were incubated at 37 °C for 15 min in 5 ml of RPMI 1640 medium containing 10% fetal calf serum and 2.5 or 11.1 mM glucose. After the incubation, islet cell extracts (50 µl) were prepared as described(3) . Release of Ca was monitored by adding the islet extracts (15-20 µl) to 3 ml of intracellular medium (3) containing 3 µM Fluo 3, a fluorescent Ca indicator, and the rat cerebellum microsome fraction (88 µg of protein) prepared as described(3) . Assay of Ca mobilizing activity using the mouse islet microsome fraction (5 µg of protein) was carried out with 0.6 ml of the intracellular medium (see Fig. 6). Fluorescence was measured at 490-nm excitation and 535-nm emission at 37 °C.


Figure 6: Effect of exogenous cADPR on Ca mobilization from islet microsomes. Islet microsomes were prepared from control mice and transgenic mice (line 18). The release of Ca from the islet microsomes (5 µg of protein) in response to various concentrations (0, 0.2, 0.35, 0.5, and 1.0 µM) of cADPR was measured as described under ``Experimental Procedures.''



Measurement of cADPR Hydrolase Activity in the Presence of Various Concentrations of ATP

The islet cell homogenate (10 µg of protein) of transgenic mice (line 18) was incubated for 20 min at 37 °C in 0.1 ml of phosphate-buffered saline (pH 7.4) in the presence of 0-6 mM ATP and 0.2 mM cADPR containing 5 µCi of [P]cADPR, prepared enzymatically from NAD and [P]NAD using Aplysia kurodai ADP-ribosyl cyclase. Reaction products were analyzed by HPLC(11, 21) .

Measurement of Serum Insulin and Blood Glucose Levels in Glucose Tolerance Tests

Transgenic mice (lines 18 and 56) and their respective nontransgenic siblings were fasted 10 h and then subjected to glucose tolerance tests by an intraperitoneal injection of 1 g of glucose/kg of body weight. Blood samples (100 µl) were taken from the tail vein at each point after glucose administration, and the serum samples (25 µl) were prepared by centrifugation after incubating blood samples overnight at 4 °C to complete coagulation. The serum insulin levels were determined by radioimmunoassay. Blood glucose determinations were made on fresh whole blood (15 µl) using the Accucheck II (Boehringer Mannheim). All statistical analyses were performed using Student's t test.


RESULTS AND DISCUSSION

The rat insulin II promoter/human CD38 hybrid gene (Ins-CD38; see ``Experimental Procedures'') was designed to direct the overexpression of CD38 in pancreatic beta cells of transgenic mice. The linearized gene fragment was microinjected into the fertilized eggs of (C57Bl/6J times CBA/J) F(1) mice. 20 out of 94 newborn mice were found to carry the Ins-CD38 transgene, as detected by polymerase chain reaction analyses using primers for the insulin promoter and human CD38 cDNA. In the present study, the six transgenic lines, 18, 30, 49, 56, 60, and 72, were maintained on ICR background and analyzed.

Northern blot analysis using the human CD38 cDNA probe (11) showed that all lines of transgenic mice but not that of the nontransgenic mice expressed human CD38 mRNA in the pancreatic islets (Fig. 1A). Densitometric scanning indicated that the transgenic lines 18, 56, and 60 expressed relatively higher levels of human CD38 mRNA in islets, whereas lines 30, 49, and 72 expressed lower levels of human CD38 mRNA. The human CD38 mRNA expression was not detected in other tissues such as brain, lung, heart, stomach, small intestine, liver, kidney, spleen, and testis in the transgenic mice (Fig. 1, B and C), indicating that the expression of human CD38 is limited to islets. In immunohistochemistry, islets of the transgenic mice were densely stained for human CD38 (Fig. 2, B and C). On the other hand, islets of the control mice showed no immunoreactivity for human CD38 (Fig. 2A). In contrast to islets, the pancreatic exocrine cells showed no detectable staining for human CD38 in any of the transgenic and nontransgenic mice.


Figure 1: Northern blot analyses of RNAs from pancreatic islets (A) and from various tissues of transgenic mouse line 18 (B) and line 56 (C) using human CD38 cDNA. A, total RNAs (1.5 µg/lane) isolated from pancreatic islets of control nontransgenic mice (C), transgenic line 18 (18), line 30 (30), line 49 (49), line 56 (56), line 60 (60), and line 72 (72) were used for RNA blot hybridization. B and C, lanes 1, brain; lanes 2, lung; lanes 3, heart; lanes 4, stomach; lanes 5, small intestine; lanes 6, liver; lanes 7, kidney; lanes 8, spleen; lanes 9, testis (lanes 1-9, 10 µg of RNA/lane). Lane 10, pancreatic islets (1.5 µg of RNA/lane). Positions of mouse 28 S and 18 S rRNAs are presented on the left. The endogenous mouse CD38 mRNA did not hybridize under the conditions used in this study.




Figure 2: Immunohistochemical detection of human CD38 in mouse pancreas. Human CD38 protein was detected in mouse islets of transgenic line 18 (B) and line 56 (C) but not in nontransgenic mouse (A).



Next, the pancreatic islet homogenates prepared from islets of transgenic and nontransgenic siblings of lines 18 and 56 were incubated with [P]NAD, and the reaction products were analyzed by HPLC. The formation of cADPR in the transgenic mice (for line 18, 1.5 nmol/minbulletmg protein; for line 56, 1.5 nmol/minbulletmg protein) was indeed much higher than in the controls (<0.05 nmol/minbulletmg protein). The formation of ADPR in the transgenic mice (for line 18, 72.8 nmol/minbulletmg protein; for line 56, 174.4 nmol/minbulletmg protein) was also much higher than in the controls (4.3 nmol/minbulletmg protein). CD38 exhibits both ADP-ribosyl cyclase and cADPR hydrolase activities, and the overall reaction is classified as an NAD glycohydrolase reaction(11, 14) . To determine the subcellular distribution of expressed CD38, islet proteins were fractionated by centrifugation (22) and fractionated proteins were assayed for NAD glycohydrolase activity (Table 1). The NAD glycohydrolase activity in the membrane fraction was greatly increased in the transgenic mice, indicating that expressed CD38 was predominantly localized in this fraction. Significant activities were also detected in the nuclear, microsome and cytosol fractions of the transgenic islets. The distribution of the percentage of total activity in fractions of transgenic mice showed a similar tendency to that of the control.



We isolated islets from transgenic mouse line 18 and their nontransgenic litter mates and measured secreted insulin after incubation in medium containing various concentrations of glucose (Fig. 3A). At 6.8-15.6 mM glucose, the transgenic insulin secretion was 1.7-2.3-fold higher than that of the control. Essentially similar results were obtained using transgenic line 56 (data not shown). Time course experiments at 11.1 mM glucose indicated that at 10 min after the exposure to glucose, the glucose-stimulated insulin secretion was significantly higher in the transgenic islets and progressively increased in a time-dependent manner (Fig. 3B).


Figure 3: Glucose-induced insulin secretion from isolated islets. A, insulin secretion from isolated islets under various glucose concentrations. The results shown are the averages from 10-25 assays performed on five different preparations of transgenic (line 18) and control islets. B, time course of insulin secretion from isolated islets under 11.1 mM glucose. n = 5 for each point. Vertical bars indicate S.E. *, p < 0.05;**, p < 0.01;***, p < 0.001.



We next investigated the effects of other insulin secretagogues on insulin secretion from transgenic and control islets. When the islets were exposed to 10 mM KIC, which, like glucose, generates ATP during the metabolism(24) , the transgenic insulin secretion was 1.7-fold higher than that of the control (Fig. 4A). Tolbutamide blocks ATP-sensitive K channel and facilitates Ca influx through voltage-dependent Ca channels (24) without increasing the islet ATP concentration(25) . When the islets were exposed to 0.2 mM tolbutamide, the transgenic insulin secretion was not altered as compared with the control (Fig. 4B). When the islets were exposed to 25 mM KCl, which directly induces cell membrane depolarization resulting in Ca influx(24) , the transgenic insulin secretion was also not significantly higher than the control (Fig. 4C).


Figure 4: Insulin secretion from isolated islets by KIC, tolbutamide, and KCl. Insulin secretion from islets of control mice and transgenic mice (line 18) stimulated by 10 mM KIC (A), 0.2 mM tolbutamide (B), or 25 mM KCl (C) was measured as described under ``Experimental Procedures.'' Open bars and shaded bars show levels from control mice and transgenic mice (line 18), respectively. n = 5 for each point. Vertical bars indicate S.E. *, p < 0.01.



We prepared cell extracts from the islets incubated in 2.5 or 11.1 mM glucose. The extracts were assayed for the Ca mobilizing activity from microsomes(3) . The Ca mobilizing activity of extracts of transgenic islets incubated in 11.1 mM glucose was 3-fold higher than that of the control extracts (Fig. 5). The Ca mobilization by the islet extracts was abolished when the microsomes had been desensitized by previously releasing Ca in response to authentic cADPR(3) , indicating that Ca mobilization by the extracts of transgenic islets after high glucose treatment is cADPR-derived. In contrast, at 2.5 mM glucose, the Ca mobilizing activities of the transgenic and control islet extracts were lower, and there was no significant difference between the two extracts (Fig. 5). The effect of exogenous cADPR on Ca mobilization from control and transgenic islet microsomes was essentially similar (Fig. 6), suggesting that microsome sensitivity to cADPR is not altered by human CD38 overexpression.


Figure 5: Ca mobilizing activity in the transgenic and control islets. Release of Ca from cerebellar microsomes by the islet extracts prepared after incubation with 2.5 or 11.1 mM glucose was measured as described under ``Experimental Procedures.'' Open bars and shaded bars show levels from control mice and transgenic mice (line 18), respectively. n = 3 for each mouse. Vertical bars indicate S.E. *, p < 0.05.



We have previously shown that ATP, generated during glucose metabolism in islets, dose-dependently inhibits the cADPR hydrolyzing activity of CD38 expressed in COS-7 cells and increases the accumulation of cADPR(11) . In fact, higher concentrations of ATP efficiently inhibited the cADPR hydrolase activity of the CD38 expressed in transgenic islets (Fig. 7). The cellular ATP concentration (^2)in transgenic islets increased from 2.3 (at 2.5 mM glucose) to 3.3 mM (at 11.1 mM glucose); this rise in cellular ATP concentrations would inhibit the cADPR hydrolase activity of CD38 and thereby increase the cADPR concentration. It is therefore reasonable to assume that the expressed ADP-ribosyl cyclase/cADPR hydrolase (CD38) in transgenic islets generates the enhanced cADPR accumulation upon stimulation by glucose or KIC to increase insulin secretion via the cADPR-mediated intracellular Ca elevation.


Figure 7: Effects of ATP on cADPR hydrolase activity of expressed CD38. ADPR synthesis from cADPR by islet cell homogenate of transgenic mice (line 18) in the presence of 0, 2, 4, or 6 mM ATP was measured as described under ``Experimental Procedures.''



Next, 10-h fasted mice were subjected to glucose tolerance tests by an intraperitoneal injection of glucose, and then serum insulin levels at each point after the glucose stimulation were determined. In transgenic mice (lines 18 and 56), glucose-induced insulin increases were 2-fold higher (at 15 min) than those of the controls (Fig. 8, A and B). Determinations of blood glucose levels at each point in the glucose tolerance test showed that the three lines of transgenic mice (lines 18, 56, and 60), which expressed higher levels of human CD38 mRNA in the pancreatic islets (Fig. 1A), had lower glucose levels than the controls (Fig. 8, C-E). However, transgenic lines 30, 49, and 72, which expressed lower levels of human CD38 mRNA in islets, did not have significantly lower glucose levels after glucose administration than the controls. These results indicate that the expressed ADP-ribosyl cyclase/cADPR hydrolase (CD38) reproducibly and dose-dependently facilitates glucose-induced insulin secretion in vivo and, by doing so, reduces the blood glucose levels of the transgenic mice.


Figure 8: Serum insulin (A and B) and blood glucose (C-E) levels in glucose-tolerance tests. A and B, transgenic mice of lines 18 and 56 and their respective nontransgenic siblings (control) were subjected to glucose-tolerance tests, and the serum insulin levels were determined as described under ``Experimental Procedures.'' n = 10 (lines 18 and 56) and 10 (respective control). C-E, in the glucose tolerance tests, blood glucose levels of lines 18, 56, and 60 and their respective nontransgenic siblings (control) were determined using whole blood taken at the indicated times from the tail vein. n = 8 (lines 18, 56, and 60) and 8 (respective control). Vertical bars indicate S.E. *, p < 0.05.



It should be noted that the production of human CD38 in islets did not appear to be deleterious to the health of the transgenic mice; fertility and body weight were indistinguishable from controls. The islets of transgenic mice at 1 year of age appeared morphologically normal and were well stained for insulin (not shown).

The results of the present study suggest that not only Ca from extracellular sources (Ca influx through voltage-dependent Ca channels evoked by glucose-induced cell membrane depolarization; (24) ) but also Ca released from intracellular stores (cADPR-induced Ca release from microsomes; (3) ) play important roles in regulating the glucose-induced insulin secretion. In fact, intracellular Ca elevation in the absence of external Ca has been reported recently(26, 27) .

The present results also indicate that CD38 plays a regulatory role in the glucose-induced insulin secretion. In non-insulin-dependent diabetes mellitus, the glucose-induced insulin secretion is impaired (28) even when pancreatic islets retain significant amounts of insulin(29) . Thus, it would be important to determine whether there are qualitative or quantitative differences in the CD38 (ADP-ribosyl cyclase/cADPR hydrolase) in non-insulin-dependent diabetes mellitus beta cells.


FOOTNOTES

*
This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture, Japan and the Uehara Memorial Foundation, Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Dept. of Biochemistry, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-77, Miyagi, Japan. Tel.: 81-22-274-1111, ext. 2211; Fax: 81-22-272-8101.

(^1)
The abbreviations used are: cADPR, cyclic ADP-ribose; ADPR, ADP-ribose; HPLC, high pressure liquid chromatography; KIC, ketoisocaproate; MES, 4-morpholineethanesulfonic acid.

(^2)
Thirty islets were incubated for 15 min in the presence of 2.5 or 11.1 mM glucose. After the incubation, the ATP level was determined by a bioluminescence assay procedure using an ATP monitoring kit (Bio Orbit, Turku, Finland) as described(30) . The ATP concentrations (in mM) were calculated on the basis of the mean diameter (220 µm) of the islets, which was measured microscopically. The ATP concentrations obtained in the present study were comparable to those reported previously (1.8-3.9 mM in (25) ).


ACKNOWLEDGEMENTS

We thank B. Bell for critical reading of the manuscript.


REFERENCES

  1. Lee, H. C., Aarhus, R., and Levitt, D. (1994) Nature Struct. Biol. 1, 143-144 [Medline] [Order article via Infotrieve]
  2. Okamoto, H., Takasawa, S., Nata, K., and Yonekura, H. (1992) Abstracts of the First Conference of the International Union of Biochemistry and Molecular Biology: Biochemistry of Diseases, Nagoya, Japan, June 1-6, 1992 (Yamashina, I., ed) p. 218, Bridge Ltd., Nagoya, Japan
  3. Takasawa, S., Nata, K., Yonekura, H., and Okamoto, H. (1993) Science 259, 370-373 [Medline] [Order article via Infotrieve]
  4. Clapper, D. L., Walseth, T. F., Dargie, P. J., and Lee, H. C. (1987) J. Biol. Chem. 262, 9561-9568 [Abstract/Free Full Text]
  5. Koshiyama, H., Lee, H. C., and Tashjian, A. H., Jr. (1991) J. Biol. Chem. 266, 16985-16988 [Abstract/Free Full Text]
  6. Currie, K. P. M., Swann, K., Galione, A., and Scott, R. H. (1992) Mol. Biol. Cell 3, 1415-1422 [Abstract]
  7. White, A. M., Watson, S. P., and Galione, A. (1993) FEBS Lett. 318, 259-263 [CrossRef][Medline] [Order article via Infotrieve]
  8. Hua, S.-Y., Tokimasa, T., Takasawa, S., Furuya, Y., Nohmi, M., Okamoto, H., and Kuba, K. (1994) Neuron 12, 1073-1079 [Medline] [Order article via Infotrieve]
  9. Sasaki, T., Shimura, S., Takasawa, S., Nagaki, M., Nara, M., Okamoto, H., and Shirato, K. (1993) Am. Rev. Respir. Dis. 147, 936 (abstr.)
  10. Higashida, H., Robbins, J., Egorova, A., Noda, M., Taketo, M., Ishizaka, N., Takasawa, S., Okamoto, H., and Brown, D. A. (1995) J. Physiol. (Lond.) 482, 317-323 [Abstract]
  11. Takasawa, S., Tohgo, A., Noguchi, N., Koguma, T., Nata, K., Sugimoto, T., Yonekura, H., and Okamoto, H. (1993) J. Biol. Chem. 268, 26052-26054 [Abstract/Free Full Text]
  12. Reinherz, E. L., Kung, P. C., Goldstein, G., Levey, R. H., and Schlossman, S. F. (1980) Proc. Natl. Acad. Sci. U. S. A. 77, 1588-1592 [Abstract]
  13. Jackson, D. G., and Bell, J. I. (1990) J. Immunol. 144, 2811-2815 [Abstract/Free Full Text]
  14. Howard, M., Grimaldi, J. C., Bazan, J. F., Lund, F. E., Santos-Argumedo, L., Parkhouse, R. M. E., Walseth, T. F., and Lee, H. C. (1993) Science 262, 1056-1059 [Medline] [Order article via Infotrieve]
  15. Koguma, T., Takasawa, S., Tohgo, A., Karasawa, T., Furuya, Y., Yonekura, H., and Okamoto, H. (1994) Biochim. Biophys. Acta 1223, 160-162 [Medline] [Order article via Infotrieve]
  16. Hanahan, D. (1985) Nature 315, 115-122 [Medline] [Order article via Infotrieve]
  17. Kato, I., Suzuki, Y., Akabane, A., Yonekura, H., Tanaka, O., Kondo, H., Takasawa, S., Yoshimoto, T., and Okamoto, H. (1994) J. Biol. Chem. 269, 21223-21228 [Abstract/Free Full Text]
  18. Lomedico, P., Rosenthal, N., Efstratiadis, A., Gilbert, W., Kolodner, R., and Tizard, R. (1979) Cell 18, 545-558 [Medline] [Order article via Infotrieve]
  19. Reddy, V. B., Thimmappaya, B., Dhar, R., Subramanian, K. N., Zain, B. S., Pan, J., Ghosh, P. K., Celma, M. L., and Weissman, S. M. (1978) Science 200, 494-502 [Medline] [Order article via Infotrieve]
  20. Okamoto, H. (1981) Mol. Cell. Biochem. 37, 43-61 [Medline] [Order article via Infotrieve]
  21. Tohgo, A., Takasawa, S., Noguchi, N., Koguma, T., Nata, K., Sugimoto, T., Furuya, Y., Yonekura, H., and Okamoto, H. (1994) J. Biol. Chem. 269, 28555-28557 [Abstract/Free Full Text]
  22. McDaniel, M. L., Colca, J. R., Kotagal, N., and Lacy, P. E. (1983) Methods Enzymol. 98, 182-200 [Medline] [Order article via Infotrieve]
  23. Karasawa, T., Takasawa, S., Yamakawa, K., Yonekura, H., Okamoto, H., and Nakamura, S. (1995) FEMS Microbiol. Lett. 130, 201-204 [CrossRef][Medline] [Order article via Infotrieve]
  24. Ashcroft, F. M., and Ashcroft, S. J. H. (1992) in Insulin: Molecular Biology to Pathology (Ashcroft, F. M., and Ashcroft, S. J. H., eds) pp. 97-150, Oxford University Press, Oxford
  25. Ashcroft, S. J. H., Weerasinghe, L. C. C., and Randle, P. J. (1973) Biochem. J. 132, 223-231 [Medline] [Order article via Infotrieve]
  26. Roe, M. W., Lancaster, M. E., Mertz, R. J., Worley, J. F., III, and Dukes, I. D. (1993) J. Biol. Chem. 268, 9953-9956 [Abstract/Free Full Text]
  27. Rojas, E., Carroll, P. B., Ricordi, C., Boschero, A. C., Stojilkovic, S. S., and Atwater, I. (1994) Endocrinology 134, 1771-1781 [Abstract]
  28. Pfeifer, M. A., Halter, J. B., and Porte, D., Jr. (1981) Am. J. Med. 70, 579-588 [Medline] [Order article via Infotrieve]
  29. Stefan, Y., Orci, L., Malaisse-Lagae, F., Perrelet, A., Patel, Y., and Unger, R. H. (1982) Diabetes 31, 694-700 [Abstract]
  30. Sandler, S., Bendtzen, K., Eizirik, D. L., Strandell, E., Welsh, M., and Welsh, N. (1990) Immunol. Lett. 26, 245-252 [CrossRef][Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.